Revolution Medicines stock is trading -23.2% below its average target price of $79.63 after marking a 3.1% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $66.0 to $104.0 per share.
The stock has an above average percentage of its shares sold short at 11.0%, and a short ratio of 9.29. The company's insiders own 1.99% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 104.0% of Revolution Medicines's shares being owned by this investor type.
Institutions Invested in Revolution Medicines
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 8% | 15,761,691 | $963,985,019 |
| 2025-06-30 | Farallon Capital Management LLC | 8% | 14,325,692 | $876,159,320 |
| 2025-06-30 | Janus Henderson Group PLC | 6% | 10,590,727 | $647,728,861 |
| 2025-06-30 | Wellington Management Group, LLP | 5% | 10,259,738 | $627,485,574 |
| 2025-06-30 | Baker Bros. Advisors, LP | 5% | 9,364,972 | $572,761,686 |
| 2025-06-30 | Blackrock Inc. | 5% | 8,661,393 | $529,730,794 |
| 2025-06-30 | FMR, LLC | 4% | 8,325,184 | $509,168,252 |
| 2025-06-30 | Nextech Invest, Ltd. | 4% | 7,601,087 | $464,882,479 |
| 2025-06-30 | Paradigm Biocapital Advisors LP | 3% | 6,093,291 | $372,665,676 |
| 2025-06-30 | BVF Inc. | 3% | 4,982,384 | $304,722,604 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Revolution Medicines.
